{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055694","form_type":"8-K","ticker":"SEER","cik":"0001726445","company_name":"Seer, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.762392+00:00","generated_at":"2026-06-02T11:49:55.966855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Seer Q1 revenue down 24% YoY to $3.1M; net loss narrows to $20.7M; authorizes $25M buyback","bullets":["Revenue $3.1M (-24% YoY); product revenue $2.5M (incl. $828K related party), service $534K.","Net loss $20.7M improved from $24.0M; gross margin 44%; operating expenses $26.6M (-10% YoY).","Cash and investments $359.2M; board authorized up to $25M share repurchase program.","FY2024 revenue guidance of $16M-$18M, essentially flat vs FY2023 revenue.","Expanding Proteograph STAC program to Europe; three new peer-reviewed publications supporting platform."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055694","json":"https://secwatch.observer/filing/0000950170-24-055694.json","markdown":"https://secwatch.observer/filing/0000950170-24-055694.md","text":"https://secwatch.observer/filing/0000950170-24-055694.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726445/000095017024055694/0000950170-24-055694-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726445/000095017024055694/ck0001726445-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T11:49:55.966855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9502ee1adb9b10e07f29425f839bb34578a5335f","claim":"Seer, Inc. reported the first quarter ended March 31, 2024 results: revenue $3.1 million. Guidance reaffirmed.","evidence_excerpt":"commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Achieved revenue of $3.1 million for the first quarter of 2024 • Announced the expansion of the Seer Technology Access Center (STAC) program to Europe, providing researchers with end-to-end services from sample","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1726445/000095017024055694/0000950170-24-055694-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}